Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

EX9:GR

2.615 EUR 0.061 2.39%

As of 09:55:59 ET on 02/27/2015.

Snapshot for Exelixis Inc (EX9)

Open: 2.565 Day's Range: 2.486 - 2.615 Volume: 500
Previous Close: 2.554 52wk Range: 1.005 - 5.490 1-Yr Rtn: -48.40%

Stock Chart for EX9

No chart data available.
  • EX9:GR 2.602
  • 1D
  • 1M
  • 1Y
2.554
Interactive EX9 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for EX9

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.8600
Est. PEG Ratio -
Market Cap (M EUR) 499.36
Shares Outstanding (M) 195.22
30 Day Average Volume 4,890
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for EX9

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for EX9

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company is building a portfolio of compounds it believes could become pharmaceutical products. Exelixis has strategic alliances with pharmaceutical and biotechnology companies.

Michael M MorrisseyPresident/CEOJeffrey J HessekielExec VP/General Counsel
Gisela M SchwabExec VP/Chief Medical OfficerPamela A SimontonExec VP
More Company Profile & Key Executives for EX9

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil